Harmony Biosciences (NASDAQ:HRMY) Announces Earnings Results

Harmony Biosciences (NASDAQ:HRMY) released its quarterly earnings data on Thursday. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.21), FiscalAI reports. The company had revenue of $215.39 million during the quarter, compared to analysts’ expectations of $220.84 million. Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The company’s revenue for the quarter was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.78 EPS.

Here are the key takeaways from Harmony Biosciences’ conference call:

• Harmony reported $215.4 million in Q1 net product revenue (up 17% YoY), about 8,500 average patients (8,600 exit), and reiterated full‑year revenue guidance of $1.0B–$1.04B.
• The company is defending a multi‑layered pitolisant IP estate after settling with 6 of 7 ANDA filers (LOE into March 2030) but faces ongoing ANDA litigation and a newly filed amorphous patent suit vs AET/Sandoz, creating legal uncertainty.
• BP‑205 is presented as a potential best‑in‑class orexin‑2 agonist with compelling preclinical data and is on track for phase I single ascending‑dose PK topline data in mid‑2026 and a U.S. IND submission later in 2026.
• Lifecycle programs are advancing — Pitolisant GR on track for NDA submission this quarter (PDUFA targeted Q1 2027), Pitolisant HD is enrolling two phase III trials (topline 2027), and Harmony has ~$878M cash to pursue BD opportunities targeting 2028–2032 revenues.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY traded down $0.43 during midday trading on Friday, reaching $30.99. 750,798 shares of the company’s stock traded hands, compared to its average volume of 879,941. The company has a fifty day simple moving average of $29.01 and a two-hundred day simple moving average of $33.04. Harmony Biosciences has a 1 year low of $25.52 and a 1 year high of $40.87. The company has a market cap of $1.79 billion, a P/E ratio of 11.44, a PEG ratio of 0.44 and a beta of 0.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.58 and a current ratio of 3.60.

Wall Street Analyst Weigh In

HRMY has been the subject of several analyst reports. Truist Financial boosted their target price on shares of Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a research note on Friday. Weiss Ratings cut shares of Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Wall Street Zen downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Zacks Research raised shares of Harmony Biosciences from a “strong sell” rating to a “hold” rating in a research note on Friday, May 1st. Finally, HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Harmony Biosciences in a research report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $40.89.

Key Harmony Biosciences News

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: Harmony Biosciences reaffirmed 2026 net revenue guidance of over $1 billion and said demand for WAKIX remained strong, which helps support the long-term outlook. Business Wire article
• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and a $55 price target, citing positive discussions with senior management and reinforcing bullish sentiment on the stock. InsiderMonkey article
• Neutral Sentiment: Several articles noted Harmony Biosciences as a small-cap value name with a relatively low forward P/E, which may attract value investors but does not directly change the near-term earnings picture. InsiderMonkey article
• Neutral Sentiment: Truist raised its price target to $29 from $25 but kept a Hold rating, suggesting only limited upside from current levels. Tickerreport article
• Negative Sentiment: Q1 earnings of $0.55 per share missed estimates of $0.76, and revenue of $215.4 million also came in below expectations, which is the main reason shares are under pressure today. Zacks article
• Negative Sentiment: Management said Q1 market access headwinds were more pronounced this year, which may raise investor concerns about near-term execution even with strong year-over-year revenue growth. Business Wire article

Hedge Funds Weigh In On Harmony Biosciences

Large investors have recently added to or reduced their stakes in the stock. National Bank of Canada FI acquired a new stake in shares of Harmony Biosciences in the third quarter valued at about $40,000. Kestra Advisory Services LLC purchased a new stake in shares of Harmony Biosciences during the fourth quarter worth about $47,000. PNC Financial Services Group Inc. raised its position in shares of Harmony Biosciences by 30.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,663 shares of the company’s stock worth $100,000 after purchasing an additional 619 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Harmony Biosciences by 338.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,511 shares of the company’s stock valued at $111,000 after buying an additional 2,711 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in Harmony Biosciences in the 2nd quarter valued at about $120,000. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.